Trade this ETF at your broker
Fund size | EUR 120 m |
Total expense ratio | 0.18% p.a. |
Replication | Physical (Full replication) |
Legal structure | ETF |
Strategy risk | Long-only |
Fund currency | EUR |
Currency risk | Currency hedged |
Volatility 1 year (in EUR) | 12.40% |
Inception/ Listing Date | 15 June 2020 |
Distribution policy | Distributing |
Distribution frequency | Quarterly |
Fund domicile | Ireland |
Fund Provider | iShares |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | State Street Fund Services (Ireland) Limited |
Investment Advisor | |
Custodian Bank | State Street Custodial Services (Ireland) Limited |
Revision Company | Deloitte |
Fiscal Year End | 30 November |
Swiss representative | BlackRock Asset Management Schweiz AG |
Swiss paying agent | State Street Bank International GmbH, Munich, Zurich Branch |
Tax data | Bundesanzeiger | |
Germany | 30% tax rebate | |
Switzerland | Unknown | |
Austria | Unknown | |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | Bank of New York Mellon|Euroclear|JP Morgan|State Street Bank |
Securities lending | Yes |
Securities lending counterparty | Barclays Bank Plc|Barclays Capital Securities Ltd.|BNP Paribas Arbitrage SNC|BNP Paribas SA|Citigroup Global Markets Ltd|Citigroup Inc|Credit Suisse Securities (Europe) Ltd.|Deutsche Bank AG|Goldman Sachs International|HSBC Bank Plc|J.P. Morgan Securities Plc|JP Morgan Chase & Co|Macquarie Bank Limited|Merrill Lynch International|Morgan Stanley & Co. International Plc|Nomura International Plc|Skandinaviska Enskilda Banken AB|Societe Generale SA|The Bank of Nova Scotia|UBS AG |
Eli Lilly & Co | 11.19% |
UnitedHealth Group | 8.50% |
Johnson & Johnson | 7.23% |
Merck & Co | 6.00% |
AbbVie | 5.79% |
Thermo Fisher Scientific | 4.10% |
Abbott Laboratories | 3.83% |
Danaher | 3.10% |
Pfizer | 2.79% |
Amgen | 2.73% |
United States | 96.21% |
Ireland | 2.49% |
Other | 1.30% |
Health Care | 98.70% |
Other | 1.30% |
YTD | +1.38% |
1 month | -4.64% |
3 months | -0.60% |
6 months | +5.43% |
1 year | +2.84% |
3 years | +10.67% |
5 years | - |
Since inception (MAX) | +34.26% |
2023 | -0.83% |
2022 | -5.83% |
2021 | +24.95% |
2020 | - |
Current dividend yield | 1.26% |
Dividends (last 12 months) | EUR 0.08 |
Period | Dividend in EUR | Dividend yield in % |
---|---|---|
1 Year | EUR 0.08 | 1.28% |
2023 | EUR 0.08 | 1.24% |
2022 | EUR 0.08 | 1.12% |
2021 | EUR 0.08 | 1.31% |
Volatility 1 year | 12.40% |
Volatility 3 years | 16.30% |
Volatility 5 years | - |
Return per risk 1 year | 0.23 |
Return per risk 3 years | 0.21 |
Return per risk 5 years | - |
Maximum drawdown 1 year | -9.32% |
Maximum drawdown 3 years | -17.20% |
Maximum drawdown 5 years | - |
Maximum drawdown since inception | -17.20% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | IUHE | - - | - - | - |
Euronext Amsterdam | EUR | IUHE | IUHE NA | IUHE.AS |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
iShares S&P 500 Health Care Sector UCITS ETF (Acc) | 1,935 | 0.15% p.a. | Accumulating | Full replication |
Xtrackers MSCI USA Health Care UCITS ETF 1D | 741 | 0.12% p.a. | Distributing | Full replication |
Invesco Nasdaq Biotech UCITS ETF | 564 | 0.40% p.a. | Accumulating | Swap-based |
iShares Nasdaq US Biotechnology UCITS ETF | 418 | 0.35% p.a. | Accumulating | Sampling |
SPDR S&P US Health Care Select Sector UCITS ETF | 351 | 0.15% p.a. | Accumulating | Full replication |